Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiation

Radiation Research

Volumn 168, Issue 5, 2007, Pages 552-559

  Epperly, Michael ^a   Jin, Shunqian ^a   Nie, Suhua ^a   Cao, Shaonan ^a   Zhang, Xichen ^a   Franicola, Darcy ^a   Wang, Hong ^a   Fink, Mitchell P ^a   Greenberger, Joel S ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PYRUVIC ACID ETHYL ESTER; RADIOPROTECTIVE AGENT; UNCLASSIFIED DRUG; PYRUVIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ENZYME ACTIVATION; FEMALE; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION INJURY; RADIATION PROTECTION; RADIOSENSITIVITY; SURVIVAL; WHOLE BODY RADIATION; ANIMAL; C57BL MOUSE; CELL LINE; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; RADIATION EXPOSURE; RADIATION RESPONSE; SURVIVAL RATE;

ANIMALIA; MUS;

ANIMALS; APOPTOSIS; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEMATOPOIETIC STEM CELLS; MICE; MICE, INBRED C57BL; PYRUVATES; RADIATION-PROTECTIVE AGENTS; SURVIVAL ANALYSIS; SURVIVAL RATE; WHOLE-BODY IRRADIATION;

EID: 38449113261     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1009.1     Document Type: Article

References (39)

1. J. S. Greenberger, M. W. Epperly, J. Gretton, M. Jefferson, S. Nie, M. Bernarding, V. Kagan and H. L. Guo, Radioprotective gene therapy. Curr. Gene Ther. 3, 183-195 (2003).
2. J. S. Greenberger and M. W. Epperly, Radioprotective antioxidant gene therapy: Potential mechanisms of action. Gene Ther. Mol. Biol. 8, 31-44(2004).
3. M. W. Epperly, S. Defilippi, C. Sikora, J. Gretton and J. S. Greenberger, Radioprotection of lung and esophagus by overexpression of the human manganese superoxide dismutase transgene. Mil. Med. 167, 71-73 (2002).
4. M. Epperly, J. E. Gretton, M. Bernarding, S. Nie, B. Rasul and J. S. Greenberger, Mitochondrial localization of superoxide dismutase is required for decreasing radiation-induced cellular damage. Radiat. Res. 160, 568-578 (2003).
5. M. W. Epperly, H. L. Guo, M. Bernarding, J. Gretton, M. Jefferson and J. S. Greenberger, Delayed intratracheal injection of manganese superoxide dismutase (MnSOD)-plasmid/liposome provides suboptimal protection against irradiation-induced pulmonary injury compared to treatment before irradiation. Gene Ther. Mol. Biol. 7, 61-68 (2003).
6. A. Tsung, T. Kaizu, A. Nakao, L. Shao, B. Bucher, M. P. Fink, N. Murase and D. A. Geller, Ethyl pyruvate ameliorates liver ischemia-reperfusion injury by decreasing hepatic necrosis and apoptosis. Transplantation 27, 196-204 (2005).
7. Y. J. Woo, M. D. Taylor, J. E. Cohen, V. Jayasankar, L. T. Bish, J. Burdick, T. Pirolli, M. F. Berry, V. Hsu and T. Grand, Ethyl pyruvate preserves cardiac function and attenuates infarct size following prolonged myocardial ischemia. J. Thorac. Cardiovasc. Surg. 127, 1262-1269 (2004).
8. Z. S. Tawadrous, R. L. Delude and M. P. Fink, Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock 17, 473-477 (2002).
9. R. Yang, D. J. Gallo, J. J. Baust, T. Uchiyama, S. K. Watkins, R. L. Delude and M. P. Fink, Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J. Physiol. Gastronitest. Liver Physiol. 283, G212-G222 (2002).
10. L. Ulloa, M. Ochani, H. Yang, D. Halperin, R. Yang, C. J. Czura, M. P. Fink and K. J. Tracey, Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. USA 99, 12351-12356 (2002).
11. R. Venkataraman, J. A. Kellum, M. Song and M. P. Fink, Resuscitation with Ringer's ethyl pyruvate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate concentrations in a rat model of lipopolysaccharide-induced shock. Shock 18, 507-512 (2002).
12. T. Miyaji, X. Hu, P. S. T. Yuen, Y. Muramatsu, S. Iyer, S. M. Hewitt and R. A. Star, Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int. 64, 1620-1631 (2003).
13. R. Yang, T. Uchiyama, S. M. Alber, X. Han, S. K. Watkins, R. L. Delude and M. P. Fink, Ethyl pyruvate ameliorates distant organ injury in a murine model of acute necrotizing pancreatitis. Crit. Care Med. 32, 1453-1459 (2004).
14. R. Yang, T. Uchiyama, S. K. Watkins, X. Han and M. P. Fink, Ethyl pyruvate reduces liver injury in a murine model of extrahepatic cholestasis. Shock 22, 369-375 (2004).
15. R. Yang, X. Han, R. L. Delude and M. P. Fink, Ethyl pyruvate ameliorates acute alcohol-induced liver injury and inflammation in mice. J. Lab. Clin. Med. 142, 322-331 (2003).
16. Y. Q. Dong, Y. M. Yao, P. Wei, H. Liu, N. Dong, Y. Yu and Z. Y. Sheng, Effects of ethyl pyruvate on cell-mediated immune function in rats with delayed resuscitation after burn injury. Chin. Crit. Care 17, 12-15 (2005).
17. T. Uchiyama, R. L. Delude and M. P. Fink, Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intensive Care Med. 29, 2050-2058 (2003).
18. P. L. Sappington, X. Han, R. Yang, R. L. Delude and M. P. Fink, Ethyl pyruvate ameliorates intestinal epithelial barrier dysfunction in endotoxemic mice and immunostimulated Caco-2 enterocytic monolayers. J. Pharmacol. Exp. Ther. 304, 464-476 (2003).
19. P. L. Sappington, M. E. Fink, R. Yang, R. L. Delude and M. P. Fink, Ethyl pyruvate provides durable protection against inflammation-induced intestinal epithelial barrier dysfunction. Shock 20, 521-528 (2003).
20. M. Song, J. A. Kellum, H. Kaldas and M. P. Fink, Evidence that glutathione depletion is a mechanism responsible for the anti-inflammatory effects of ethyl pyruvate in cultured LPS-stimulated RAW 264.7 cells. J. Pharmacol. Exp. Ther. 308, 307-316 (2004).
21. N. Albright, Computer programs for the analysis of cellular survival data. Radiat. Res. 112, 331-340 (1987).
22. H. B. Stone, C. N. Coleman, J. E. Moulder, K. K. Ang, M. S. Anscher, M. H. Barcellos-Hoff, W. S. Dynan, J. R. Fink, D. J. Grdina and M. Z. D. Wolpert, Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Radiat. Res. 162, 711-718 (2004).
23. A. K. Salahudeen, E. C. Clark and K. A. Nath, Hydrogen peroxide-induced renal injury; A protective role for pyruvate in vitro and in vivo. J. Clin. Invest. 88, 1886-1893 (1991).
24. R. Bunger, R. T. Mallet and D. A. Hartman, Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart. Near-complete prevention of reperfusion contractile failure. Eur. J. Biochem. 180, 221-233 (1989).
25. L. Cicalese, K. Lee, W. Schraut, S. Watkins, A. Borle and R. Stanko, Pyruvate prevents ischemia-reperfusion mucosal injury of rat small intestine. Am. J. Surg. 171, 97-100 (1999).
26. P. Sileri, S. Schena, S. Morini, C. Rastellini, S. Pham, E. Benedetti and L. Cicalese, Pyruvate inhibits hepatic ischemia-reperfusion injury in rats. Transplantation 72, 27-30 (2001).
27. S. K. Gupta, I. Mohanty, D. Trivedi, R. Tandon, S. Srivastava and S. Joshi, Pyruvate inhibits galactosemic changes in cultured cat lens epithelial cells. Ophthalmic Res. 34, 23-28 (2002).
28. W. Zhao, P. S. Devamanoharan, M. Henein, A. H. Ali and S. D. Varma, Diabetes-induced biochemical changes in rat lens: attenuation of cataractogenesis by pyruvate. Diabetes Obes. Metab. 2, 165-174 (2000).
29. J. Y. Lee, Y. H. Kim and J. Y. Koh, Protection by pyruvate against transient forebrain ischemia in rats. J. Neurosci. 21, 1-6 (2001).
30. P. N. Slovin, C. J. Huang, J. R. Cade, C. E. Wood, O. Nasiroglu, M. Privette, P. Orbach and J. W. Skimming, Sodium pyruvate is better than sodium chloride as a resuscitation solution in a rodent model of profound hemorrhagic shock. Resuscitation 50, 109-115 (2001).
31. S. D. Varma, P. S. Devamanoharan, A. R. Rutzen, A. H. Ali and M. Henein, Attenuation of galactose-induced cataract by pyruvate. Free Radic. Res. 30, 253-263 (1999).
32. W. Zhao, P. S. Devamanoharan and S. D. Varma, Fructose induced deactivation of antioxidant enzymes: preventive effect of pyruvate. Free Radic. Res. 33, 23-30 (2000).
33. S. D. Varma, P. S. Devamanoharan and A. H. Ali, Prevention of intracellular oxidative stress to lens by pyruvate and its ester. Free Radic. Res. 28, 131-135 (1998).
34. A. P. Halestrap, S. J. Clarke and S. A. Javadov, Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc. Res. 61, 372-385 (2004).
35. A. P. Halestrap, K-Y. Woodfield and C. P. Connern, Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J. Biol. Chem. 272, 3346-3354 (1997).
36. L. L. Pearce, M. W. Epperly, J. S. Greenberger, B. R. Pitt and J. Peterson, Identification of respiratory complexes I and III as mitochondrial sites of damage following exposure to ionizing radiation and nitric oxide. Nitric Oxide 5, 128-136 (2001).
37. M. P. Rigobello, F. Turcato and A. Bindoli, Inhibition of rat liver mitochondrial permeability transition by respiratory substrates. Arch. Biochem. Biophys. 319, 225-230 (1995).
38. A. P. Halestrap, C. P. Connern, E. J. Griffiths and P. M. Kerr, Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischemia/reperfusion injury. Mol. Cell. Biochem. 174, 167-172 (1997).
39. 2+. Neurochem. Res. 28, 1201-1211 (2003).